Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
June 12, 2018
Tyme Releases Detailed Data and Analyses with SM-88 From the First Human Study and Compassionate Use Programs
NEW YORK, June 12, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), a clinical-stage biotechnology company developing cancer therapeutics, today release detailed patient data and ...
June 12, 2018
STRATA Skin Sciences to Present at JMP 2018 Life Sciences Conference
HORSHAM, Pa., June 12, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, ...
June 12, 2018
Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors
SANTA MONICA, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced ...
June 12, 2018
FDA Grants Rare Pediatric Disease Designation to A4250; Albireo Eligible to Apply for Priority Review Voucher
BOSTON, June 12, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
June 11, 2018
AgeX Therapeutics Closes on $5 Million Strategic Investment From Juvenescence
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), focused on prolonging healthspan through an understanding of the fundamental mechanisms of human ...
June 11, 2018
MediWound Completes Enrollment in NexoBrid® U.S. Phase 3 DETECT Study
YAVNE, Israel, June 11, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn ...
June 11, 2018
Neovasc Announces Appointment of Steve Rubin as Chairman of the Board and General Update
VANCOUVER, June 11, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral ...
June 11, 2018
Achaogen Highlights Multiple Plazomicin Presentations at ASM Microbe 2018 Annual Meeting
SOUTH SAN FRANCISCO, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative ...
June 11, 2018
INVENTIVA to Present at the 2018 JMP Securities Life Sciences Conference
Daix (France), June 11, 2018 - Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) ...
June 11, 2018
Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the appointment of Jayson Dallas, M.D., as ...
June 11, 2018
Pfenex and Alvogen Enter into U.S. Agreement for Commercialization of PF708, a Therapeutic Equivalent Candidate to Forteo®
SAN DIEGO, June 11, 2018 (GLOBE NEWSWIRE) -- Pfenex (NYSE American:PFNX) and Alvogen today announced entering into an agreement granting Alvogen exclusive rights to commercialize ...
June 8, 2018
BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX Shares
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced that a draft registration statement on Form 10 was ...
June 8, 2018
Zealand Pharma achieves milestone in first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes
Copenhagen, 8 June, 2018 - Zealand Pharma A/S ("Zealand") announces that the primary and key secondary objectives of the first multinational Phase 3 clinical trial of ...
June 8, 2018
Albireo Elects Anne Klibanski and Stephanie Okey to Board of Directors
BOSTON, June 08, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
June 8, 2018
ADMA Biologics Announces Pricing of Public Offering of Common Stock
RAMSEY, N.J. and BOCA RATON, Fla., June 08, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) announced today the pricing of ...
June 8, 2018
Oncobiologics Closes Second Tranche of $15 Million Private Placement
CRANBURY, N.J., June 08, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (ONS) (the “Company”) today announced that it has closed on the second, and final, tranche ...
June 7, 2018
Lipocine Announces Dosing in Ambulatory Blood Pressure Study for TLANDO™
SALT LAKE CITY, June 7, 2018 /PRNewswire/ -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, today announced the dosing of the first subject in the ambulatory ...
June 7, 2018
Brainsway and Cohen Veterans Bioscience Announce Biomarker Research Collaboration in Post Traumatic Stress Disorder
HACKENSACK, N.J., June 07, 2018 (GLOBE NEWSWIRE) --  Brainsway Ltd. (BRIN.TA), a leader in the advanced non-invasive treatment of brain disorders, and Cohen Veterans Bioscience, ...
June 7, 2018
MannKind Successfully Completes Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension Advancing Development to Next Phase
WESTLAKE VILLAGE, Calif., June 07, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced that it has completed a Phase 1 clinical study of Treprostinil ...
June 7, 2018
Paratek Demonstrates Breadth of Omadacycline Clinical and Microbiological Data at ASM Microbe 2018
BOSTON, June 07, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK) announced today that data from its omadacycline clinical and microbiology programs will be presented ...
Page 66 of 150